Effect of Melatonin on Schizophrenic Symptoms: a Randomized Placebo-Controlled Trial

NAActive, not recruitingINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

December 5, 2024

Primary Completion Date

June 5, 2025

Study Completion Date

June 5, 2025

Conditions
Schizophrenia DisordersPsychotic Disorder
Interventions
DRUG

Melatonin

Participants in this group will receive 6 mg of melatonin orally, administered as two 3 mg tablets 30 minutes before bedtime daily for 8 weeks, alongside their standard antipsychotic treatment (risperidone 6-8 mg/day).

DRUG

Placebo

Participants in this group will receive placebo tablets identical in shape, size, smell, taste, and color to melatonin tablets, administered in the same manner (two tablets 30 minutes before bedtime) for 8 weeks, alongside their standard antipsychotic treatment (risperidone 6-8 mg/day).

Trial Locations (1)

54000

Lahore General Hospital, Lahore, Lahore

All Listed Sponsors
lead

Lahore General Hospital

OTHER_GOV

NCT06838104 - Effect of Melatonin on Schizophrenic Symptoms: a Randomized Placebo-Controlled Trial | Biotech Hunter | Biotech Hunter